Get the Stockscreener App
437.33
0.30%
-1.33
After Hours:
437.33
United Therapeutics Corp stock is traded at $437.33, with a volume of 618.31K.
It is down -0.30% in the last 24 hours and down -3.47% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$438.66
Open:
$432.75
24h Volume:
618.31K
Relative Volume:
0.81
Market Cap:
$19.73B
Revenue:
$3.08B
Net Income/Loss:
$1.24B
P/E Ratio:
17.08
EPS:
25.6108
Net Cash Flow:
$1.07B
1W Performance:
+5.29%
1M Performance:
-3.47%
6M Performance:
+48.45%
1Y Performance:
+16.06%
1-Day Range:
$430.02
$440.00
1-Week Range:
$415.26
$479.50
52-Week Range:
$266.98
$479.50
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.63B | 260.53M | 4.77B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
Access Investment Management LLC Makes New $2.14 Million Investment in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation $UTHR Position Lessened by Bessemer Group Inc. - MarketBeat
Combining machine learning predictions for United Therapeutics CorporationMarket Performance Recap & Verified Technical Trade Signals - newser.com
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease - The Joplin Globe
United Therapeutics (Nasdaq: UTHR) starts EXPAND with first UKidney xenotransplant - Stock Titan
Can technical indicators confirm United Therapeutics Corporation’s reversalWeekly Stock Report & High Accuracy Swing Trade Signals - newser.com
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of Stock - MarketBeat
United Therapeutics Hits Day High with 9.63% Surge in Stock Price - Markets Mojo
Is United Therapeutics Corporation (UTH) stock a top dividend aristocrat candidateRisk Management & Reliable Entry Point Trade Alerts - newser.com
MSN Money - MSN
United Therapeutics Corp. Hits New 52-Week High of $479.50 - Markets Mojo
United Therapeutics posts record revenue but misses Q3 earnings expectations - MSN
Focus Partners Advisor Solutions LLC Buys Shares of 1,440 United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp’s Earnings Call Highlights Growth and Innovation - MSN
United Therapeutics CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
3rd Circ. Preview: BMW, MiLB And Sandoz Top Nov. Lineup - Law360
United Therapeutics (NASDAQ:UTHR) Given New $423.00 Price Target at Wells Fargo & Company - MarketBeat
Assetmark Inc. Boosts Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Will United Therapeutics Corporation stock benefit from upcoming earnings reportsOptions Play & Technical Pattern Alert System - newser.com
United Therapeutics Executives Sell Shares - TradingView
United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Wells Fargo Maintains United Therapeutics (UTHR) Equal-Weight Recommendation - Nasdaq
United Therapeutics (NASDAQ:UTHR) Reaches New 12-Month High After Better-Than-Expected Earnings - MarketBeat
United Therapeutics price target raised to $587 from $569 at RBC Capital - TipRanks
United Therapeutics price target raised to $447 from $435 at Morgan Stanley - TipRanks
United Therapeutics (UTHR) Earnings Transcript - AOL.com
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2025 Earnings Call Transcript - Insider Monkey
United Therapeutics’ AI-Driven Study: A Potential Game-Changer for Pulmonary Hypertension Diagnosis - MSN
United Therapeutics’ PHINDER Study: A Step Forward in Early Detection of Pulmonary Hypertension - MSN
Silver Spring-based United Therapeutics reports Q3 earnings - Maryland Daily Record
Published on: 2025-10-31 23:58:52 - newser.com
United Therapeutics Reports Record Q3 2025 Results - TipRanks
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus
United Therapeutics: Q3 Earnings Snapshot - CT Insider
United Therapeutics (NASDAQ:UTHR) COO Sells $9,393,750.00 in Stock - MarketBeat
Why Is United Therapeutics (UTHR) Stock Soaring Today - Yahoo Finance
United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark - TradingView
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday - Benzinga
United Therapeutics Q3 2025 Earnings ReportRevenue & Profit AnalysisNews and Statistics - IndexBox
United Therapeutics Q3 2025 Earnings: Profit Beats ForecastsNews and Statistics - IndexBox
United Therapeutics (UTHR) Beats Q3 Earnings Estimates - Yahoo Finance
United Therapeutics Grows Revenue, But Misses Earnings Forecast - Finimize
United Therapeutics Corp Q3 2025 Earnings: EPS of $7.16 Beats Es - GuruFocus
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings - Yahoo Finance
United Therapeutics Corp Announces Rise In Q3 Bottom Line - Nasdaq
United Therapeutics misses Q3 expectations despite record revenue - Investing.com
United Therapeutics misses Q3 expectations despite record revenue By Investing.com - Investing.com Philippines
United Therapeutics Q3 revenue misses estimates - TradingView
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results - TradingView
UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):